Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database

被引：0
|
作者：
Elisabetta Poluzzi
Emanuel Raschi
Ariola Koci
Ugo Moretti
Edoardo Spina
Elijah R. Behr
Miriam Sturkenboom
Fabrizio De Ponti
机构：
[1] University of Bologna,Department of Medical and Surgical Sciences, Pharmacology Unit, Alma Mater Studiorum
[2] University of Verona,Clinical Pharmacology Unit
[3] University of Messina,Department of Clinical and Experimental Medicine
[4] St. George’s University of London,Cardiovascular Sciences Research Centre
[5] Erasmus Medical Center,undefined
来源：
Drug Safety | 2013年 / 36卷
关键词：
Olanzapine; Aripiprazole; Ziprasidone; Paliperidone; Amisulpride;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：467 / 479
页数：12
相关论文
共 50 条
  • [1] Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
    Poluzzi, Elisabetta
    Raschi, Emanuel
    Koci, Ariola
    Moretti, Ugo
    Spina, Edoardo
    Behr, Elijah R.
    Sturkenboom, Miriam
    De Ponti, Fabrizio
    [J]. DRUG SAFETY, 2013, 36 (06) : 467 - 479
  • [2] An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database
    Hsin-wei Wang
    Alan M. Hochberg
    Ronald K. Pearson
    Manfred Hauben
    [J]. Drug Safety, 2010, 33 : 1117 - 1133
  • [3] An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database
    Wang, Hsin-wei
    Hochberg, Alan M.
    Pearson, Ronald K.
    Hauben, Manfred
    [J]. DRUG SAFETY, 2010, 33 (12) : 1117 - 1133
  • [4] Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS)
    Stamoula, Eleni
    Stamatellos, Vasileios-Periklis
    Vavilis, Theofanis
    Dardalas, Ioannis
    Papazisis, Georgios
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 239 - 245
  • [5] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    [J]. DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [6] Triptans and Serious Cardiovascular Events: Possible Safety Signals from the FDA Adverse Event Reporting System Database
    Roberto, Giuseppe
    Piccinni, Carlo
    Biagi, Chiara
    Koci, Ariola
    Motola, Domenico
    Vaccheri, Alberto
    Montanaro, Nicola
    Poluzzi, Elisabetta
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 438 - 438
  • [7] Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
    Xiang, Dao-Chun
    Chen, Wei
    Fu, Zhi-Wen
    Wu, Xin-Hua
    Gao, Ping
    Wu, Yue
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (10) : 943 - 955
  • [8] Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
    Gatti, Milo
    Antonazzo, Ippazio Cosimo
    Diemberger, Igor
    De Ponti, Fabrizio
    Raschi, Emanuel
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (09) : 983 - 989
  • [9] ‘Extreme Duplication’ in the US FDA Adverse Events Reporting System Database
    Manfred Hauben
    Lester Reich
    James De Micco
    Katherine Kim
    [J]. Drug Safety, 2007, 30 : 551 - 554
  • [10] Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database
    Dong-Eun Seo
    Seonji Kim
    Byung-Joo Park
    [J]. Clinical Drug Investigation, 2020, 40 : 873 - 881
12345